Imatinib for Gastrointestinal Stromal Cancer
Trial Summary
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot participate if you are using certain drugs that affect liver enzymes (CYP3A or CYP3A4) or are on oral warfarin. It's best to discuss your current medications with the trial team.
What data supports the effectiveness of the drug Imatinib for treating gastrointestinal stromal cancer?
Imatinib, a drug that targets specific cancer cell growth signals, has been shown to improve survival in patients with gastrointestinal stromal tumors (GISTs), especially when traditional chemotherapy is ineffective. Studies have reported good responses in cases of advanced GISTs, with many patients experiencing remission or disease stabilization.12345
Is imatinib safe for treating gastrointestinal stromal tumors?
What makes the drug imatinib unique for treating gastrointestinal stromal cancer?
Imatinib is unique because it specifically targets and inhibits the KIT protein, which is often mutated and overactive in gastrointestinal stromal tumors, leading to uncontrolled cell growth. This targeted approach is more effective than traditional chemotherapy, which generally has poor results for this type of cancer.511121314
What is the purpose of this trial?
Imatinib can lead to long recurrence free survival in patients diagnosed with gastrointestinal stromal tumors (GIST); however side effects can significantly hinder quality of life for our patients. This study will use therapeutic drug monitoring to improve quality of life and symptoms and assess how many patients maintain therapeutic levels. Free drug levels and pharmokinetics of imatinib will also be monitored.
Research Team
Reema Patel, MD
Principal Investigator
University of Kentucky
Eligibility Criteria
Adults over 18 with a specific type of tumor called GIST and certain genetic mutations can join. They should be starting or have recently started taking Imatinib, have good performance status, and normal organ function. Those with uncontrolled illnesses, on warfarin, other cancer treatments within 6 months without disease evidence, or allergies to Imatinib cannot participate.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive imatinib with therapeutic drug monitoring to improve quality of life and symptoms
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Imatinib
Imatinib is already approved in European Union, United States, Canada, Japan, Switzerland for the following indications:
- Chronic myeloid leukemia
- Gastrointestinal stromal tumors
- Dermatofibrosarcoma protuberans
- Systemic mastocytosis
- Hypereosinophilic syndrome
- Chronic myeloid leukemia
- Gastrointestinal stromal tumors
- Dermatofibrosarcoma protuberans
- Systemic mastocytosis
- Hypereosinophilic syndrome
- Chronic myeloid leukemia
- Gastrointestinal stromal tumors
- Dermatofibrosarcoma protuberans
- Systemic mastocytosis
- Hypereosinophilic syndrome
- Chronic myeloid leukemia
- Gastrointestinal stromal tumors
- Dermatofibrosarcoma protuberans
- Systemic mastocytosis
- Hypereosinophilic syndrome
- Chronic myeloid leukemia
- Gastrointestinal stromal tumors
- Dermatofibrosarcoma protuberans
- Systemic mastocytosis
- Hypereosinophilic syndrome
Find a Clinic Near You
Who Is Running the Clinical Trial?
Reema A. Patel
Lead Sponsor